


# Acute Renal Failure

---


usually a consequence

- Definitions
- Pathogenesis
- Classification
- ICU Incidence/ Significance
- Treatments


# Prerenal Azotaemia





# Prerenal Azotaemia



# Prerenal Azotaemia







# Prerenal Azotaemia

---


## Prerenal Azotaemia

---

Urine Osmolality (mOsm/Kg)	>500
Urine Sodium (mmol/l)	<20
Urine/ Plasma Creatinine ratio	>40
FE <sub>Na</sub>	<1%
FE <sub>Urea</sub>	<35%
Urinary Sediment	occasional hyaline or fine granular casts


# Pathogenesis: Vascular Factors

---



# Pathogenesis: Vascular Factors



---





↓ Renal Blood Flow

Oxygen Demand ↑


# Pathogenesis: Vascular Factors




# Pathogenesis: Vascular Factors



# Pathogenesis: Vascular Factors



# Pathogenesis: Vascular Factors



# Acute Renal Failure

---

## Prerenal Azotaemia

---

Urine Osmolality (mOsm/Kg)	>500
Urine Sodium (mmol/l)	<20
Urine/ Plasma Creatinine ratio	>40
FE <sub>Na</sub>	<1%
FE <sub>Urea</sub>	<35%
Urinary Sediment	occasional hyaline or fine granular casts


# Acute Renal Failure

---

	Prerenal Azotaemia	Acute Renal failure
Urine Osmolality (mOsm/Kg)	>500	<400
Urine Sodium (mmol/l)	<20	>40
Urine/ Plasma Creatinine ratio	>40	<40
FE <sub>Na</sub>	<1%	>2%
FE <sub>Urea</sub>	<35%	>35%
Urinary Sediment	occasional hyaline or fine granular casts	tubular cells, coarse granular casts

# Pathogenesis: Tubular Factors


---



 Na/K ATPase


# Pathogenesis: Tubular Factors

---



# Pathogenesis: Tubular Factors


---



# Pathogenesis: Tubular Factors

---

Sloughing of Viable Epithelial Cells



Necrosis

 Na/K ATPase


# Pathogenesis: Tubular Factors

---

Sloughing of Viable Epithelial Cells

Necrosis

Inflammatory Infiltration




 Na/K ATPase

# Pathogenesis: Tubular Factors

---

Kidney stem cells




Adjacent tubule cells

Haematopoietic cells

 Na/K ATPase

# Pathogenesis: Tubular Factors

---




 Na/K ATPase

# Pathogenesis: Summary

---


## Initiation

- Prerenal azotaemia
- Loss of autoregulation
- ↑ Intracellular calcium
- ATD Depletion
- Oxidative injury



## Extension

- Loss of tubular cell polarity
- Cell necrosis
- Medullary congestion
- ↓↓ GFR
- Inflammatory infiltration




## Maintenance

- Tubular histology is rebuilt by:
- Adjacent tubule cells
  - Kidney stem cells
  - Haematopoietic cells



## Repair

Polarity and function restored




# Pathogenesis: Summary

---


## Initiation

- Prerenal azotaemia
- Loss of autoregulation
- ↑ Intracellular calcium
- ATD Depletion
- Oxidative injury




## Extension

- Loss of tubular cell polarity
- Cell necrosis
- Medullary congestion
- ↓↓ GFR
- Inflammatory infiltration




## Maintenance

- Tubular histology is rebuilt by:
- Adjacent tubule cells
  - Kidney stem cells
  - Haematopoietic cells



## Repair

Polarity and function restored




# Pathogenesis: Summary

---


## Initiation

- Prerenal azotaemia
- Loss of autoregulation
- ↑ Intracellular calcium
- ATD Depletion
- Oxidative injury




## Extension

- Loss of tubular cell polarity
- Cell necrosis
- Medullary congestion
- ↓↓ GFR
- Inflammatory infiltration




## Maintenance

- Tubular histology is rebuilt by:
- Adjacent tubule cells
  - Kidney stem cells
  - Haematopoietic cells



## Repair

Polarity and function restored




# Pathogenesis: Summary

---


## Initiation

- Prerenal azotaemia
- Loss of autoregulation
- ↑ Intracellular calcium
- ATD Depletion
- Oxidative injury




## Extension

- Loss of tubular cell polarity
- Cell necrosis
- Medullary congestion
- ↓↓ GFR
- Inflammatory infiltration




## Maintenance

- Tubular histology is rebuilt by:
- Adjacent tubule cells
  - Kidney stem cells
  - Haematopoietic cells



## Repair


Polarity and function restored




# Pathogenesis: Tubular Factors

---

Extension Phase



Maintenance Phase



# RIFLE

the Acute Dialysis Quality Initiative

---

# RIFLE

the Acute Dialysis Quality Initiative

---

Risk

Injury

Failure

} Indicator Classes

# RIFLE

the Acute Dialysis Quality Initiative

---

Risk

Injury

Failure

} Indicator Classes

---

Loss

End-stage Kidney Disease

} Outcome Classes

Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, the ADQI workgroup: **Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.** *Crit Care* 2004, **8**:R204-R212

# RIFLE: Classification

---

	GFR (Serum Creatinine)	Urine Output (ml/Kg/hr)
<b>R</b> isk	x 1.5	< 0.5 for 6 hours
<b>I</b> njury	6.1%	< 0.5 for 12 hours
<b>F</b> ailure	4.4%	< 0.3 for 24 hours or anuria for 12 hours
<b>L</b> oss	Complete loss of kidney disease > 4 weeks	
<b>E</b> nd-stage	Complete loss of kidney disease > 3 months	

# RIFLE: In Practice

- n = 5383 patients
- Pittsburgh University Hospital 2006

E A Hoste, G Clermont, A Kersten et al: **RIFLE criteria for acute kidney injury**. *Crit Care* 2006, **10**:R73

	At Admission	Ever	Mortality (HR)
No ARF	78%	33%	
<b>R</b> isk	8%	12%	1.0 (0.68 - 1.56)
<b>I</b> njury	7%	27%	1.4 (1.02 - 1.88)
<b>F</b> ailure	7%	28%	2.7 (2.03 - 3.55)

# RIFLE: In Practice

- n = 5383 patients
- Pittsburg University Hospital 2006

E A Hoste, G Clermont, A Kersten et al: **RIFLE criteria for acute kidney injury**. *Crit Care* 2006, **10**:R73

	At Admission	Ever	Mortality (HR)
No ARF	78%	33%	
Risk	8%	12%	1.0 (0.68 - 1.56)
Injury	7%	27%	1.4 (1.02 - 1.88)
Failure	7%	28%	2.7 (2.03 - 3.55)

52%

# Preventions

---

- Cause Prevention
- Loop Diuretics
- Osmotic Diuretics
- Ca Channel Blockers
- N-Acetylcysteine
- Theophyllines

# Treatments

- Loop Diuretics
- Natriuretic Peptides
- Dopamine/ Fenoldopam
- Dialysis Mode
- Dialysis Dosing

# Prevention & Treatment: Frusemide

---

- Inhibits Na/K/Cl channel in ascending Loop-of-Henley
- Reduced intracellular substrate for Na/K ATPase
- Reduced energy consumption in the critical outer medulla (by 45% in-vitro)
- Wash out tubular debris

# Prevention & Treatment: Frusemide

---

- 9 RCT
- n = 849
- In or at risk of ARF
- Heterogeneous selection criteria
- Many methodological problems
- Ototoxic

K M Ho, D J Sheridan: **Meta-analysis of frusemide to prevent or treat acute renal failure.** *BMJ* 2006, doi:10.1136/bmj.38902.605347.7C



# Prevention & Treatment: Frusemide

## Renal Replacement Therapy

## Mortality


Prevention

Treatment



# Prevention: Ca Channel Blockers

Kribben, A, et al. **Evidence for role of cytosolic free calcium in hypoxia-induced proximal tubule injury.** J. Clin. Invest. 1994;93:1922-1929



# Prevention: Ca Channel Blockers

---

- n = 210
- Better serum creatinine at 3 months and 12 months post for patients receiving live or cadaveric kidney transplant
- Poor quality evidence.
- Adverse effects not reported.
- Other, trials (cumulatively larger) limited to cadaveric transplants have failed to find a benefit

V Riemsdijk, et al. **Isradipine results in a better renal function after kidney transplant.**  
*Transplantation.* 2000;70:122-126

# Treatment: Dopamine/ Fenoldopam

---

- Based on the vasomotor nephropathy model
- Correct aberrant vascular responses and improve renal blood supply
- Good in-vitro evidence to show improved RBF & GFR

# Treatment: Dopamine/ Fenoldopam

---

- 58 RCT
- n = 2149
- No difference from placebo in mortality or renal replacement therapy
- This review did not list adverse effects but we know dopamine can cause:
  - Extravasation necrosis
  - Arrhythmias
  - Headaches

Kellum J A, Decker J M: **The use of dopamine in acute renal failure: a meta-analysis.** *Crit Care Med* 2001;29:1526-1531

# Treatment: Dialysis Dose

---

- The biggest RCT
- n = 425
- CVVHF
- 20 / 30 / 45 (ml/Kg/hour)
- Low dose substantially inferior to higher two cohorts
- Three-way comparison:
  - RR = 1.88 (1.14 - 1.67)
  - NNT = 7 (4 - 16)

Ronco C, Bellomo R, Homel et al. **Effects of different doses in continuous veno-venous haemofiltration on outcomes of renal failure.** *Lancet* 2000;356:26-30

# Interventions: Summary

---

## Prevention

Cause Prevention

Loop Diuretics

Osmotic Diuretics

Ca Channel Blockers

N-Acetylcysteine

Theophyllines

## Treatment

Loop Diuretics

Natriuretic Peptides

Dopamine

Dialysis Mode

Dialysis Dosing

# Interventions: Summary

---

## Prevention

---

Cause Prevention



Loop Diuretics

Osmotic Diuretics

Ca Channel Blockers

N-Acetylcysteine

Theophyllines

## Treatment

---

Loop Diuretics

Natriuretic Peptides

Dopamine

Dialysis Mode

Dialysis Dosing

# Interventions: Summary

---

## Prevention

Cause Prevention



Loop Diuretics



Osmotic Diuretics

Ca Channel Blockers

N-Acetylcysteine

Theophyllines

## Treatment

Loop Diuretics

Natriuretic Peptides

Dopamine

Dialysis Mode

Dialysis Dosing

# Interventions: Summary

---

	<u>Prevention</u>	<u>Treatment</u>
Cause Prevention	✓ ✓	Loop Diuretics
Loop Diuretics	↔	Natriuretic Peptides
Osmotic Diuretics	↔	Dopamine
Ca Channel Blockers		Dialysis Mode
N-Acetylcysteine		Dialysis Dosing
Theophyllines		

# Interventions: Summary

---

	<u>Prevention</u>	<u>Treatment</u>
Cause Prevention	✓ ✓	Loop Diuretics
Loop Diuretics	↔	Natriuretic Peptides
Osmotic Diuretics	↔	Dopamine
Ca Channel Blockers	↔	Dialysis Mode
N-Acetylcysteine		Dialysis Dosing
Theophyllines		

# Interventions: Summary

---

	<u>Prevention</u>	<u>Treatment</u>
Cause Prevention	✓ ✓	Loop Diuretics
Loop Diuretics	↔	Natriuretic Peptides
Osmotic Diuretics	↔	Dopamine
Ca Channel Blockers	↔	Dialysis Mode
N-Acetylcysteine	✓	Dialysis Dosing
Theophyllines		

# Interventions: Summary

---

	<u>Prevention</u>	<u>Treatment</u>
Cause Prevention	✓ ✓	Loop Diuretics
Loop Diuretics	↔	Natriuretic Peptides
Osmotic Diuretics	↔	Dopamine
Ca Channel Blockers	↔	Dialysis Mode
N-Acetylcysteine	✓	Dialysis Dosing
Theophyllines	↔	

# Interventions: Summary

---

	Prevention		Treatment
Cause Prevention	✓ ✓	Loop Diuretics	↔
Loop Diuretics	↔	Natriuretic Peptides	
Osmotic Diuretics	↔	Dopamine	
Ca Channel Blockers	↔	Dialysis Mode	
N-Acetylcysteine	✓	Dialysis Dosing	
Theophyllines	↔		

# Interventions: Summary

---

	<u>Prevention</u>		<u>Treatment</u>
Cause Prevention	✓ ✓	Loop Diuretics	↔
Loop Diuretics	↔	Natriuretic Peptides	↔
Osmotic Diuretics	↔	Dopamine	
Ca Channel Blockers	↔	Dialysis Mode	
N-Acetylcysteine	✓	Dialysis Dosing	
Theophyllines	↔		

# Interventions: Summary

---

	Prevention		Treatment
Cause Prevention	✓ ✓	Loop Diuretics	↔
Loop Diuretics	↔	Natriuretic Peptides	↔
Osmotic Diuretics	↔	Dopamine	↔
Ca Channel Blockers	↔	Dialysis Mode	
N-Acetylcysteine	✓	Dialysis Dosing	
Theophyllines	↔		

# Interventions: Summary

---

	Prevention		Treatment
Cause Prevention	✓ ✓	Loop Diuretics	↔
Loop Diuretics	↔	Natriuretic Peptides	↔
Osmotic Diuretics	↔	Dopamine	↔
Ca Channel Blockers	↔	Dialysis Mode	↔
N-Acetylcysteine	✓	Dialysis Dosing	
Theophyllines	↔		

# Interventions: Summary

---

	Prevention		Treatment
Cause Prevention	✓ ✓	Loop Diuretics	↔
Loop Diuretics	↔	Natriuretic Peptides	↔
Osmotic Diuretics	↔	Dopamine	↔
Ca Channel Blockers	↔	Dialysis Mode	↔
N-Acetylcysteine	✓	Dialysis Dosing	✓ High dose
Theophyllines	↔		

# Questions

# Key points

---

- RIFLE is the future of ARF research
- Preventing the causes of ARF is our best strategy
- Frusemide for fluid management only